Mereo reports Phase II data for COPD candidate acumapimod

Mereo BioPharma Group plc (LSE:MPH) reported top-line data from a Phase II trial in 282 patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) showing that low- and high-dose acumapimod (BCT-197) plus standard of care (SOC) both met the primary endpoint of improving forced expiratory volume in 1 second (FEV1) at day seven compared to baseline (p≤0.001 and p=0.012, respectively). Placebo plus SOC did not significantly improved FEV1 at day seven compared to baseline (p=0.102) and Mereo said there was no significant difference on the endpoint between treatment groups.

High-dose acumapimod plus SOC did significantly reduce the incidence of clinical treatment failures by >50% as measured by the number of rehospitalizations for COPD at days 90-150 vs. placebo. Acumapimod was well tolerated...